DAGCO Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 3.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,817 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. DAGCO Inc.’s holdings in Pfizer were worth $392,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Pfizer by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after purchasing an additional 6,965,496 shares during the last quarter. Norges Bank bought a new position in Pfizer during the 4th quarter worth $2,219,532,000. Morgan Stanley boosted its stake in Pfizer by 16.4% in the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock valued at $1,973,389,000 after buying an additional 7,540,245 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 42,009,283 shares of the biopharmaceutical company’s stock valued at $1,546,362,000 after acquiring an additional 2,012,367 shares in the last quarter. Finally, Sanders Capital LLC raised its stake in shares of Pfizer by 10.6% during the fourth quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock valued at $1,280,997,000 after acquiring an additional 3,051,838 shares during the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.
A number of research analysts have recently issued reports on PFE shares. JPMorgan Chase & Co. set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, February 3rd. Royal Bank of Canada started coverage on Pfizer in a research report on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 target price for the company. Mizuho decreased their target price on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, February 3rd. SVB Leerink dropped their target price on Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research report on Thursday, April 1st. Finally, Berenberg Bank reissued a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a report on Tuesday, March 23rd. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $38.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The business had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the previous year, the business earned $0.55 earnings per share. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Shareholders of record on Friday, May 7th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a yield of 3.90%. Pfizer’s dividend payout ratio is presently 52.88%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Featured Article: Market Indexes
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.